Report: UK cannot be a world leader in life sciences when patients cannot access drugs

31 July 2017

The disconnect between the UK government’s target to make the country a world leader in the life sciences, and its failure to provide patients with the drugs that result from this science, has been underlined by a new report.

Every one of the top 20 global pharma firms has a presence in the UK, including the US drug giant Pfizer (NYSE: PFE), which commissioned the report, carried out by PwC Strategy and entitled Driving Global Competitiveness of the UK’s Life Sciences Ecosystem.

The reason for commissioning the report, according to Erik Nordkamp, managing director of Pfizer UK, was to inform the company’s response to the government’s Industrial Strategy consultation as it looks to strengthen a globally competitive life sciences sector.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK